Choroidal Neovascularization | A Drug Pipeline Analysis Report 2018 | Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest pipeline analysis report on the drug pipeline for choroidal neovascularization. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat choroidal neovascularization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005248/en/

Technavio has published a new report on the drug development pipeline for choroidal neovascularization, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Choroidal neovascularization: Market overview

Choroidal neovascularization is the creation of new blood vessels in the choroid layer of the eye. It is a common cause of neovascular degenerative maculopathy, which is also known as wet macular degeneration. Extreme myopia, malignant myopic degeneration, or age-related developments commonly exacerbate choroidal neovascularization.

According to a senior market research analyst at Technavio, “Choroidal neovascularization can be detected by using a type of perimetry called preferential hyperacuity perimetry. Based on fluorescein angiography, the choroidal neovascularization may be described as classic or occult. Two other tests that help identify the condition include indocyanine green angiography and optical coherence tomography.”

Choroidal neovascularization: Segmentation analysis

This pipeline analysis report segments the choroidal neovascularization market based on therapies employed (monotherapy and monotherapy/combination therapy), RoA (intravitreal), therapeutic modality (monoclonal antibody, recombinant fusion protein, oligonucleotide, recombinant protein and small molecule), targets (tissue factor, VEGF-A, TK, VEGF-A and ANG-2, TGF- β, and VEGF-A and PIGF), MoA (angiogenesis inhibitor, VEGF-A inhibitor, TK inhibitor, VEGF-A and ANG-2 inhibitor, TGF- β inhibitor, and VEGF-A and PIGF inhibitor), geographical segmentation (US), and recruitment status (completed and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, around 29% of the molecules that are being investigated for the treatment of choroidal neovascularization are monoclonal antibodies.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

• Drugs under development
• Indications coverage

Drug Development Strategies

• Therapies employed
• RoA
• Therapeutic modality
• Geographical coverage

Recruitment Strategies

• Recruitment status
• Gender
• Age

Key Companies

• Type of players
• Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180813005248/en/